The Role of Droperidol in the Management of Acute Agitation: A Comprehensive Review

BACKGROUND: Acute behavioral disturbance accounts for ~1.7 million emergency department visits in the USA annually, with 83% involving an underlying serious mental illness. A 2001 FDA black box warning regarding QT prolongation reduced use of droperidol, a butyrophenone antipsychotic, but recent data challenge these concerns. METHODS: We reviewed randomized controlled trials, systematic reviews, and observational studies from 2000 to 2025 assessing droperidol's efficacy and safety. RESULTS: Droperidol provides rapid, effective sedation, with onset within 3 to 10 minutes and median time to adequate sedation of 14 to 25 minutes. Sixty-four percent of patients achieved adequate sedation at 15 minutes with droperidol versus 25% to 35% with ziprasidone and 29% with lorazepam. QT prolongation occurred in 1.3% of 1009 patients, mostly those with pre-existing risk factors. Respiratory depression was less common with droperidol (12%) than with ziprasidone (36% to 39%) or lorazepam (48%). Droperidol-midazolam combinations achieved faster sedation and reduced need for rescue medications (41% vs. 62%). Droperidol-treated patients had shorter hospital stays. Large studies found negligible rates of torsades de pointes or extracardiac arrhythmias. Elderly and pediatric patients responded favorably to low-dose droperidol. The American College of Emergency Physicians now recommends droperidol as first-line treatment for severe agitation. Combined with benzodiazepines, droperidol shows synergistic effects and allows lower doses of both with fewer adverse effects. CONCLUSIONS: Recent evidence contradicts earlier FDA concerns, supporting droperidol as a safe, effective treatment for acute agitation. Its rapid onset, efficacy, safety profile, and operational benefits, including shorter ED stay, support its return to routine clinical practice.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Psychopharmacology
Published
2026-11-19
DOI
https://doi.org/10.1097/jcp.0000000000002292
Primary Topic
Anesthesia and Sedative Agents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Role of Droperidol in the Management of Acute Agitation: A Comprehensive Review

Zeeshan Mansuri, Garima Yadav, Sreshta Jeelugu, Malav Patel et al.
2 links
Journal of Clinical Psychopharmacology
Anesthesia and Sedative Agents
article

The Role of Droperidol in the Management of Acute Agitation: A Comprehensive Review

Zeeshan Mansuri, Garima Yadav, Sreshta Jeelugu, Malav Patel, Srajan Gupta, Shivani Malavia, Hetansh Shah
article en

Abstract

BACKGROUND: Acute behavioral disturbance accounts for ~1.7 million emergency department visits in the USA annually, with 83% involving an underlying serious mental illness. A 2001 FDA black box warning regarding QT prolongation reduced use of droperidol, a butyrophenone antipsychotic, but recent data challenge these concerns. METHODS: We reviewed randomized controlled trials, systematic reviews, and observational studies from 2000 to 2025 assessing droperidol's efficacy and safety. RESULTS: Droperidol provides rapid, effective sedation, with onset within 3 to 10 minutes and median time to adequate sedation of 14 to 25 minutes. Sixty-four percent of patients achieved adequate sedation at 15 minutes with droperidol versus 25% to 35% with ziprasidone and 29% with lorazepam. QT prolongation occurred in 1.3% of 1009 patients, mostly those with pre-existing risk factors. Respiratory depression was less common with droperidol (12%) than with ziprasidone (36% to 39%) or lorazepam (48%). Droperidol-midazolam combinations achieved faster sedation and reduced need for rescue medications (41% vs. 62%). Droperidol-treated patients had shorter hospital stays. Large studies found negligible rates of torsades de pointes or extracardiac arrhythmias. Elderly and pediatric patients responded favorably to low-dose droperidol. The American College of Emergency Physicians now recommends droperidol as first-line treatment for severe agitation. Combined with benzodiazepines, droperidol shows synergistic effects and allows lower doses of both with fewer adverse effects. CONCLUSIONS: Recent evidence contradicts earlier FDA concerns, supporting droperidol as a safe, effective treatment for acute agitation. Its rapid onset, efficacy, safety profile, and operational benefits, including shorter ED stay, support its return to routine clinical practice.

Journal of Clinical Psychopharmacology
New York Medical College (US), Yale University (US), Gujarat Cancer Society (IN), Sri Venkateswara Medical College and Ruia Hospital (IN), Government Medical College (IN), Yale New Haven Health System (US), GCS Medical College (IN)
Good health and well-being
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon